Nektar Therapeutics (NKTR) Earnings Call Transcript & Summary
February 25, 2021
Earnings Call Speaker Segments
Jennifer Ruddock
executiveThanks, Crystal, and good afternoon, everyone. We appreciate you being with us today. Joining us on this call are Howard Robin, our President and CEO; Gil Labrucherie, our COO and CFO; Dr. Jonathan Zalevsky, our Chief of Research and Development; and Dr. Brian Kotzin, our Interim Chief Medical Officer and Head of Development. During today's call, we anticipate making forward-looking statements about our business, including clinical trial enrollment and clinical trial results, the timing of and plans for upcoming clinical trials, the timing of and plans for future clinical data presentations, the therapeutic potential of our drug candidates, outcomes of and plans for health authority regulatory actions and decisions, estimates and predictions concerning the COVID-19 pandemic's impact on our business and clinical trials, financial guidance, and certain other statements regarding the future of our business. Since these forward-looking statements concern the future, they carry inherent uncertainties and risks that are hard to predict, and many of which lie outside our control. Important risks and uncertainties appear in the Form 10-Q filed on November 6, 2020, which can be found at www.sec.gov. We assume no obligation to update any of these forward-looking statements, whether due to new information, future developments or otherwise. A webcast of this call will be accessible on the IR page of Nektar's website at nektar.com. Before I turn the call over to Howard, I want to remind you that I will be moderating the Q&A session for our team, since we are all in different locations, so that we can avoid technical issues during the session. We appreciate your patience as we work to make sure there are no technology disruptions for those listening on the call today; having said that, I will hand the call over to our President and CEO, Howard Robin. Howard?
Howard Robin
executiveThank you, Jennifer. I appreciate everyone taking the time to be with us today. Nektar has achieved outstanding strides over the last 12 months in establishing our organization as a frontrunner in creating cytokine therapeutics. What's key is that we effectively expanded the registrational solid tumor program for bempeg, our lead IL-2 asset, by adding several registrational trials covering adjuvant melanoma, muscle invasive bladder cancer, and, most recently, head and neck cancer. In addition, we managed to finish enrollment for the Nektar-sponsored registrational trials already underway in renal cell carcinoma and bladder cancer, surmounting the obstacles the pandemic created during this past year. With our IL-15 program, we launched a fresh development approach, moving forward two distinct Phase 1/2 clinical studies to pair NKTR-255 alongside leading ADCC compounds rituximab and daratumumab in liquid tumors, as well as cetuximab in solid tumors. Turning to NKTR-358, our Treg stimulator, we along with our partner Eli Lilly expanded the clinical program by adding four mid-stage studies across various autoimmune disorders, which include a Phase 2 in lupus, a Phase 2 study in ulcerative colitis, and two Phase 1b studies — one in psoriasis and the second in atopic dermatitis. We've also strengthened our already solid financial standing through a $150 million royalty financing in December and a novel $150 million risk sharing collaboration, just finalized with Blackstone Life Sciences and Abingworth via their SFJ entity, to completely fund the trial for bempeg plus pembro in head and neck cancer, and we're collaborating with Merck on this study. Our extensive pipeline of candidates spanning immuno-oncology and immunology, combined with a robust cash balance, puts Nektar in a strong position as we head into 2021. So let me start today with bempeg, our most advanced late-stage clinical program — an IL-2 pathway agonist being developed alongside checkpoint inhibitors nivolumab and pembrolizumab. Our approach for bempeg centers on going after multiple large frontline and adjuvant tumor settings: melanoma, renal cell carcinoma, bladder cancer, non-small-cell lung cancer, and head and neck cancer. The chance to combine bempeg with PD-1 inhibitors across these tumor settings is substantial. Sales of PD-1s in 2020 across these settings exceeded $5 billion, and we took great pride in establishing a development program that puts us in position to capture meaningful value with bempeg. During the past year, we and BMS launched two new registrational studies for bempeg plus nivolumab, and both aim at large patient populations. The first, in adjuvant melanoma, is sponsored by Nektar, while the second, in muscle-invasive bladder cancer, is sponsored by BMS. Beyond that, BMS also kicked off a Phase 2 study in renal cell carcinoma for bempeg plus nivo with a TKI, setting the stage for future development of a TKI-inclusive regimen in the first-line RCC setting. That study is built to capitalize on their recent successful approval of nivo plus cabo, and we're eager to press ahead with it. In addition, Nektar moved forward with a Phase 2 trial of our own that goes by the name PROPEL, which is evaluating bempeg together with pembro in non-small cell lung cancer patients. And only a week ago, we disclosed a pair of distinct partnerships intended to finance and push ahead a fresh registrational trial of bempeg plus pembro in first-line head and neck cancer. Let me offer a few quick remarks about these newly announced partnerships. To begin, we signed a clinical trial collaboration and drug supply agreement with Merck covering a Phase 2/3 trial of bempeg plus pembro against pembro alone in metastatic head and neck cancer patients whose tumors express PD-L1. This trial is built so that we can seek global registration of bempeg for this indication, and we feel a great deal of gratitude about working with Merck for the first time on bempeg. For this 500-patient trial, Merck will supply pembro free of charge, and the company is likewise working alongside us on the protocol and the study design. In this setting, pembro has risen to become the top checkpoint inhibitor and the standard of care, surpassing the extreme regimen and the way it is used in first-line care, and we are enthusiastic about what bempeg might do for these patients. JZ will go into further detail regarding this trial and why an IL-2 agent makes sense for this indication. Next, in order to finance this trial in a way that is non-dilutive, we signed a highly inventive agreement with SFJ, an organization supported by Blackstone Life Sciences and Abingworth, under which they have committed $150 million. We are glad that SFJ and its investors demonstrated their confidence in bempeg by putting up this capital entirely at risk; that highlights their view that bempeg could potentially win approval across multiple tumor settings; as consideration, once bempeg is approved, we owe a set of success-based milestone payments to be paid across roughly seven years. Crucially, once again, those payments are triggered only if bempeg obtains FDA approval, and they begin only after the head and neck trial finishes, which is presently expected in 2024, with our expectation of a possible first payment of $30 million in 2025. We project that this new head and neck cancer opportunity might reach as much as $500 million to $800 million worldwide annually, so it amounts to a considerable addition of value to the bempeg development program. From the very beginning, we had imagined bempeg being developed alongside checkpoint inhibitors other than nivolumab. Our initial agreement with BMS gave us the right to run independent trials outside the indications being chased under the Nektar-BMS joint development plan currently under way with nivo. When it comes to pembro, the two biggest metastatic settings carrying monotherapy labels are non-small-cell lung cancer and head and neck cancer. Thanks to this new head and neck trial, we now have a strategy for tackling both of those tumor types, and we are doing so by pairing with the unmistakable market leader in those settings. As a reminder, our arrangement with BMS includes $1.43 billion payable upon filing approval milestones for bempeg across the U.S., Europe, and Japan. Those payments hinge on any approval of bempeg, independent of whether nivo is part of it. For the first indication, we can get $625 million tied to filings and approvals, plus $260 million for every one of the following three indications, once again no matter if the filing and approval involve a combination with nivo or pembro. Since six registrational studies could back potential filings, we have numerous chances to collect these milestones. During SITC last November, we shared fresh data on patients in our metastatic melanoma cohort from PIVOT-02; that data showed how bempeg can assist melanoma patients in reaching a substantial decrease in tumor burden and proved the ongoing advantage of the doublet treatment as time goes on. Among patients who responded, 90% saw a 100% reduction in target lesions, or a complete response, to the investigational doublet treatment, and we recognize in this context that depth of response may lead to better PFS and OS. For the bempeg plus nivo cohort, median PFS came in at 30.9 months, which stands out favorably against the historical 6.9 months for nivo by itself in the Checkmate 067 study.
Howard Robin
executiveJust to remind everyone, in the Phase 3 trial we're running for these patients, nivo monotherapy serves as the comparator arm. That means the findings shared at SITC give us still greater confidence in what bempeg might achieve therapeutically. We also reported, for the very first time, a two-year landmark overall survival number for bempeg combined with nivo, which came to 77%, and the median overall survival still hasn't been reached. These results also stack up well against the OS figures for nivo by itself, where the two-year landmark OS was 59%. More recently, we shared news of really strong enrollment momentum in the Nektar-sponsored PROPEL trial, which is testing bempeg alongside pembro in first-line non-small cell lung cancer patients. That trial is going to give us the crucial data we need to shape a Phase 3 approach in this setting together with pembro. As we noted at the JPMorgan conference, this study enrolled far faster than anticipated, with a large volume of patients signing up during November and December of last year. Our plan is to disclose the first set of data from this trial during the second half of this year. Those data will cover roughly 60 patients, distributed among three distinct PD-L1 expression cohorts. In a bit, JZ will go deeper on PROPEL, and he'll also give everyone an update on what we're doing with bempeg in the COVID-19 study. Now shifting to NKTR-255, our other major I-O cytokine program, which works through a broad mechanism that drives natural killer cell proliferation along with expansion of CD8 T cells and memory cells. When we pair NKTR-255 with the top approved ADCC antibodies — all of which need functioning natural killer cells to work as intended — we think we can boost the therapeutic potential of those targeted antibody treatments for patients. At the most recent SITC conference, we presented highly encouraging early clinical results in multiple myeloma and Non-Hodgkin's lymphoma patients, showing that NKTR-255 raises NK cell levels in these individuals, and we showed the clinical benefit of NKTR-255 given as a single agent in those early dose cohorts. Beyond the trial that's already underway in blood cancers, we're also signing up patients for our Phase 1 solid tumor study. We anticipate having more data from these trials during the second half of this year. NKTR-358 is the third cytokine in our portfolio, and it's being advanced together with Eli Lilly to tackle a wide array of autoimmune and inflammatory conditions, each of which involves substantial patient populations. We're genuinely thrilled about Lilly's level of commitment to this program, and Brian will discuss it further later in the call. After last year's positive results for NKTR-358 in lupus patients, Lilly kicked off a Phase 2 trial in lupus with 280 patients, and it's now also starting a 200-patient Phase 2 trial in ulcerative colitis — both of which come on top of the separate Phase 1b studies already running in psoriasis and atopic dermatitis. As we head into 2021, our balance sheet is incredibly solid, featuring $1.2 billion in cash and zero debt. At this point, I'll hand things over to JZ, who will go into more detail about our bempeg, NKTR-262, and NKTR-255 programs. JZ?
Jonathan Zalevsky
executiveThanks, Howard. I'll kick things off by briefly walking through the bempeg results from the PIVOT-02 melanoma cohort that were shared at SITC. As Howard mentioned, median PFS came in at 30.9 months. The overall response rate stood at 53%, and 34% of patients had a complete response. Equally important, the median depth of response we saw was 78.5%. These findings stand out when set against historical figures from published literature on depth of response for single-agent nivo and ipi/nivo, which came in at 35% and 52%, respectively. As we've noted previously, an FDA meta-analysis of melanoma trials demonstrated that depth of response in target lesions is strongly correlated with better PFS and OS. And sure enough, with our median PFS of 30.9 months, the correlation we've seen lines up closely with that FDA meta-analysis. Median overall survival for this cohort hasn't been reached yet; however, as Howard said earlier, our two-year landmark OS was considerably stronger than the historical rates documented for the current standards of care in this setting, nivo as well as ipi/nivo. This data bolsters our confidence as we move forward with our ongoing bempeg trials, which include five ongoing registrational trials, and with the upcoming study in head and neck cancer, we'll soon have six registrational studies in total. Let me now turn to an update on the first-line metastatic melanoma study, which our partner BMS is running. As a reminder, back in 2019 we were granted a breakthrough therapy designation for bempeg plus nivo, based on the high complete response rate seen in this setting. In the second Phase 3 study, comparing the doublet against single-agent nivo, we have three primary endpoints: overall response rate, or ORR, progression free survival, or PFS, and overall survival, or OS. The ORR endpoint was set up as a possible early submission opportunity for the bempeg plus nivo combination, while the PFS endpoint was intended to support a possible full approval. As you're aware, BMS is conducting this study, and at present we expect they might have initial data from this trial at some point in the window of late this year or the first part of 2022. PFS is an event-driven analysis, and several other factors, such as how quickly PFS events accumulate, could affect this timing. The study's original design assumes a median PFS for the nivolumab arm comparable to the 6.7 months seen in the Checkmate 067 study. The next study where we anticipate Phase 3 data is our first-line renal cell carcinoma study. We have finished enrollment in this study, and based on our original projections for the study design and modeling of the TKI comparator arm, we project that we could hit our first interim analysis on the primary endpoint of overall survival at some point in the first half of 2022, in line with our prior guidance. Given the initial results we've seen for bempeg combined with nivo in renal cell carcinoma, BMS and Nektar are pursuing a broad development strategy for bempeg in that indication. As Howard mentioned before, BMS has also just launched a Phase 1/2 trial in RCC that pairs bempeg plus nivo alongside a TKI, letting us evaluate that regimen against a nivo/TKI combination and thereby clear the way for a TKI-containing approach in RCC for the doublet too. Turning to the registrational trial in first-line cisplatin-ineligible urothelial carcinoma, we hit our target for enrollment last summer. That trial is meant to support a possible accelerated approval submission. To remind everyone, the co-primary endpoints there are ORR and duration of response, assessed through central radiology review, in roughly 100 cisplatin-ineligible urothelial carcinoma patients whose baseline PD-L1 status is positive or whose CPS score is 10 or lower. Duration of response matters enormously in this population, since that measure was the distinguishing factor behind accelerated approvals granted to single-agent checkpoint inhibitors here, when weighed against the gemcitabine/carboplatin standard of care regimen. For this trial, our aim is a median follow-up of 18 months in order to assess duration of response, which puts the timing of our first data from the study at the middle of 2022. We have two sizable Phase 3 trials that extend our efforts in urothelial carcinoma and melanoma. The first is the muscle-invasive bladder cancer trial, conducted by BMS, which is enrolling about 540 patients assigned to either bempeg plus nivo or nivo alone across a 12-month treatment period after surgery. Because of the trial's size, we anticipate the initial data readouts in 2024. This trial is also intended to act as a confirmatory study for a possible accelerated approval in the cis-ineligible urothelial carcinoma study. The second is the adjuvant melanoma trial, a key additional Phase 3 registrational study that we launched in the third quarter of 2020 and which is now actively enrolling. It will enroll 950 patients, with a 12-month treatment period following surgery and event-free survival as the endpoint. This trial is meant to establish bempeg as a standard of care for melanoma treatment, building on the recent approval of nivo in that setting. In melanoma, the study substantially expands the number of patients who could benefit from our agent. We expect initial data from this trial in 2024 as well. To build on what Howard mentioned before, regarding PROPEL—our trial involving non-small cell lung cancer paired with pembro—we've seen tremendous enthusiasm from top thoracic cancer centers participating in this research. And, as we noted at JPMorgan, that enthusiasm translated into enrollment during the final 2 months of 2020 that surpassed what we'd anticipated, even though many companies conducting very early stage trials were dealing with COVID-related site difficulties. We plan to share findings on the 3 PD-L1 expresser subgroups from the trial—under 1%, 1 to 49%, and 50% or higher—during the latter half of this year. We expect to have roughly 60 patients who've undergone at least 2 scans distributed among those subgroups. This trial is structured to demonstrate the advantage of the bempeg plus pembro combination relative to historical response rates seen with pembro alone. When it comes to non-small cell lung cancer, we understand that the level of underlying inflammation within the tumor microenvironment strongly influences how well a single-agent checkpoint inhibitor like pembro performs. And in fact, the brilliant researchers at Merck were fully aware of this and developed what has become the standard diagnostic framework for classifying non-small cell lung cancer according to PD-L1 expression status. The fundamental categorization of under 1%, 1 to 49%, and 50% or higher PD-L1 expression in the tumor biopsy effectively established the measure of inflammation in a tumor microenvironment, with those at 50% or above having the highest level; as a result, we observe the most significant advantage from single-agent pembro when treating this particular subgroup. Bempeg's mechanism is quite potent since it aims at and elevates the inflammatory condition of the tumor microenvironment.
Jonathan Zalevsky
executiveBempeg accomplishes this through encouraging T-cell infiltration, boosting expression of effector cytokines such as interferon gamma and the genes downstream of it, and also raising PD-1 expression on lymphocytes along with PD-L1 expression on tumor tissue. Adding bempeg's MOA alongside pembro in non-small cell lung cancer is something we're quite thrilled about, and our belief is that combining these mechanisms synergistically might enhance how well the doublet works across several PD-L1 expression subgroups; we also recently added a chemo combination into the PROPEL study so that we could potentially incorporate the doublet plus chemo option into our Phase 2 strategy. Data coming out of PROPEL is going to let us build a Phase 2 plan for bempeg in non-small cell lung cancer, and we look forward to sharing that data during the second half of 2021. Regarding our new registrational Phase 2/3 head and neck cancer trial, we are sponsoring it alongside Merck, who collaborates with us on the protocol. This study involves 500 patients, with overall survival serving as the primary endpoint; our plan is to launch the trial in the second half of this year. As Howard mentioned before, SFJ is going to fund the study, and they'll assist Nektar in operationalizing it as well. This trial has been designed to back a possible global registration for the bempeg plus pembro doublet. An interim analysis of ORR is built in after the initial 200 patients get enrolled. Should ORR clear a prespecified futility boundary, the study keeps going, the other 300 patients get enrolled into the Phase 3 portion, and OS as the primary endpoint gets evaluated across all 500 patients; we're extremely enthusiastic about what this doublet might do to increase and deepen responses compared with pembro by itself in this immune-sensitive cancer, particularly considering the data seen when combining bempeg plus nivo in melanoma and other immune-sensitive cancers. In the past, IL-2 has demonstrated activity in head and neck cancer, with multiple published studies covering both the metastatic and adjuvant settings, and developing bempeg plus pembro here is something we're very excited about. On top of that, few late-stage studies are currently underway in this front-line indication. That's why we view this as a unique opening for us to establish the bempeg backbone as a first-line IL-2 mechanism in head and neck cancer. And finally, before I move on to NKTR-255 and NKTR-262, I'd like to briefly mention our study of bempeg in adult patients with mild COVID-19 infection; we remain on track to report data from this study by the middle of this year. As a reminder, back in November, we initiated this Phase 1b study, a randomized double-blind placebo-controlled trial evaluating safety, tolerability and the PK/PD profile of a single dose of bempeg administered to adult patients with mild COVID-19. In this initial trial, we are enrolling as many as 30 adult patients with a confirmed COVID-19 infection who have mild symptomology. So, what we mean by this is an oxygen saturation level higher than 93% while not receiving supplemental oxygen, a breathing rate under 20 breaths each minute, and a heart rate that stays below 90 beats each minute. There will be 3 cohorts in this trial, and each cohort can include no more than 10 patients. Randomization is happening on a one-to-one basis, so patients get either a single dose of bempeg or a placebo. The main goals of this study involve determining how well bempeg is tolerated in people with mild COVID, assessing how immune activation shifts as time goes on, and pinpointing a dose that can be recommended for the subsequent trial. When it comes to secondary endpoints, we're also following whether supplemental oxygen becomes necessary and checking clinical status using a 10-point ordinal scale across 30 days following administration of bempeg, plus we're including SARS-CoV-2 serology and immune cell profiling throughout that same period. Once this initial Phase 1b study wraps up successfully, we intend to move bempeg's development forward into patients with moderate COVID-19, where it would be given alongside standard of care. We're looking at a strategy that pairs bempeg with one standard of care treatment, like remdesivir, and compares that against standard of care by itself; our hope is that this distinctive method might eventually lower disease severity and boost recovery time, along with cutting down hospitalization time, for moderate COVID-19 patients who need to be hospitalized and have a low lymphocyte count; this approach would merge an antiviral mechanism with one that encourages T-cell responses, which we think could particularly benefit those patients who cannot mount an adequate T-cell response against the virus on their own. Shifting to NKTR-262, which is our TLR agonist. This study continues, with patients receiving treatment at the recommended Phase 2 dose together with bempeg or bempeg plus nivo. The group being studied consists of relapsed refractory melanoma patients following checkpoint inhibitor therapy, with roughly 20 patients in each arm; enrollment for these two cohorts has now been completed, and we're eager to share data from this trial later in the year. Let's now discuss NKTR-255, our IL-15 agonist program and the next cytokine therapy we have in clinical development. As Howard mentioned before, the scientific community widely acknowledges the IL-15 mechanism as a strong way to engage natural killer cell biology when treating cancer; and we see potential for something like NKTR-255, which engages the entire biology of the IL-15 pathway, to be used alongside various mechanisms in different contexts. Our initial clinical effort centers on ADCC combination, and we've built a clinical plan to combine it with leading ADCC approaches in both liquid and solid tumor settings. The first of these is our Phase 1/2 study involving patients with relapsed refractory hematologic malignancy, where we presented data from the initial group of patients treated with NKTR-255 at SITC 2020. In this group of patients with myeloma or Non-Hodgkin's lymphoma who were highly refractory, NKTR-255 proved biologically active and produced steady lymphocyte expansion, with NK and CD8 T cells showing lasting, sustained gains. According to our findings, NKTR-255 drove a fivefold increase in NK cells and a threefold increase in CD8 T cells. What's more, proliferative capacity stayed intact through multiple cycles of NKTR-255, peaking at roughly eight to 10 days during each cycle; we also presented case studies involving two patients who had received very heavy prior treatment, in whom disease progression was kept in check across multiple cycles of NKTR-255. Among those two patients, one showed a metabolic response; beyond that, we saw signs of CD19 CAR T cell increases in a single patient given NKTR-255 many weeks following CAR T therapy. It was encouraging to find that NKTR-255 had a favorable tolerability profile, with low-grade cytokine-related AEs that proved transient and simple to manage, and NKTR-255 showed a half-life of about 30 hours, with no indication of drug accumulation under this every three weeks dosing schedule; we anticipate finishing the monotherapy dose escalation portion of the trial in the first part of 2021, with data slated for presentation later this year. After dose escalation wraps up, we will move into several arms, each enrolling roughly 20 patients. In the first arm, NKTR-255 will be assessed as a monotherapy at the recommended Phase 2 dose among NHL patients who have already progressed after CD19 CAR T.
Jonathan Zalevsky
executiveFor arm number two, we're going to look at NKTR-255 paired with cetuximab in follicular lymphoma or low grade NHL patients who are in third-line or beyond. Arm three involves testing NKTR-255 alongside Darzalex Faspro in multiple myeloma patients at third-line or greater; late last year we signed a drug supply collaboration with Janssen covering Darzalex Faspro supply for that trial. Since getting approval in May of last year, the subcutaneous version of Darzalex keeps gaining a larger portion of the franchise, and we're quite happy to collaborate with Janssen on including Darzalex Faspro in our NKTR-255 study. Our other Phase 1/2 trial is testing NKTR-255 combined with cetuximab across two separate groups of heavily pretreated, late-line metastatic colorectal cancer or head and neck cancer patients. Dosing has already begun in that study, and our enrollment target is 80 patients across the U.S. and Europe. As everyone knows, in these settings cetuximab's response rate is quite low, roughly 10% or 15%. So our aim is to do better than that by adding NKTR-255. This later-line setting carries a significant unmet need, and should we show a higher response rate, multiple potential paths forward for NKTR-255 would open up. The trial starts with a dose finding stage for the combo, which will subsequently expand into dedicated cohorts for colorectal cancer and head and neck cancer patients. We anticipate having some initial data from that dose finding stage later this year. At this point I'll hand the call to Brian, who will go over the NKTR-358 program in greater detail.
Brian Kotzin
executiveThank you, JZ. Just as Howard mentioned before, our partner Eli Lilly has expanded the scope of the NKTR-358 program and moved it forward, and that makes us quite happy. After encouraging results in lupus patients during the prior year, Lilly launched a Phase 2 trial in lupus, and at this point it is kicking off a Phase 2 study in ulcerative colitis, while also advancing the pair of separate Phase 1b trials in psoriasis and atopic dermatitis. There are strong grounds for targeting the T regulatory cell, or Treg, mechanism when treating autoimmune diseases, and this rests on a large body of evidence showing that a faulty, unbalanced immune system underlies the clinical symptoms seen in these conditions. A number of autoimmune and inflammatory conditions, such as systemic lupus and ulcerative colitis, come with lower Treg counts, diminished Treg activity and/or less IL-2 being produced. Through NKTR-358, we aim to tackle these Treg abnormalities and create an IL-2 like molecule capable of stimulating Tregs selectively, doing so more selectively than native low dose IL-2 would. Last November, at the yearly American College of Rheumatology meeting, we presented fresh findings from our Phase 1b trial of NKTR-358 in people suffering mild to moderate lupus. We described how lupus skin disease activity improved with NKTR-358. Only patients with mild to moderate lupus were enrolled, and each received just three doses of NKTR-358 given every two weeks, meaning the trial was not built specifically to gauge efficacy; even so, we felt highly encouraged that for one of our exploratory endpoints, NKTR-358 produced a dose-dependent drop in lupus skin disease activity as measured by the CLASI activity score among a subset of 18 patients whose baseline score was greater than or equal to four. Those patients saw their activity scores get better, whereas those in the placebo arm showed no decrease in their scores. A score reduction of four or more points occurred in seven of the 18 patients, especially at the two highest doses given during the study, 12 micrograms and 24 micrograms per kilogram, and this became evident by day 43 relative to baseline. Building on what I said before, we are aware that the literature contains substantial data demonstrating that among lupus patients, circulating Treg numbers and function can fall considerably while disease is active. Notably, we observed a dose-dependent and profound rise in Tregs and Treg subsets brought about by NKTR-358; thus we were glad to see signs of this mechanistic rationale appearing with NKTR-358 treatment in the patients enrolled in our study; this exciting data prompted Lilly to start a Phase 2 trial in patients with moderate to severe lupus. In that Phase 2 lupus study, 280 patients are being randomized to one of three NKTR-358 doses or placebo, given every two weeks across a 24-week treatment period. The primary endpoint of the Phase 2 study is the percentage of patients who achieve at least a four point reduction on the SLEDAI-2K scale. Additional goals consist of the proportion of individuals showing an SRI-4 response, a BICLA response based on BILAG, plus attainment of low disease activity as set out by the lupus low disease activity state, or LLDAS; we'll further describe pharmacokinetics, pharmacodynamics, and immunogenicity among those receiving treatment. These measures will be taken at week 24, and we anticipate finishing the study in 18 to 24 months. This quarter, Lilly is likewise launching a Phase 2 randomized placebo-controlled trial involving ulcerative colitis patients. Just as with lupus, the literature holds substantial proof regarding Tregs' involvement in inflammatory bowel conditions like ulcerative colitis. Lower counts and diminished function of Treg cells have been observed among such patients, and evidence also indicates that an improper ratio between working Tregs and T effector cells within the intestinal microenvironment plays a part in inflammatory lesions. Thus we're eager to investigate this further inflammatory condition using NKTR-358 and to grow the program alongside our collaborator Lilly. During the initial induction phase, the trial will assess multiple dose levels through an adaptive design. A total of 200 patients are slated for enrollment, and the study's endpoint is the proportion of patients who reach clinical remission following induction treatment at 12 weeks. Beyond that, we understand Lilly intends to start further Phase 2 studies over the coming 12 to 18 months in immune-mediated indications that remain undisclosed. We're happy about Lilly's swift progress on the program and their interest in developing this agent across a broad range of inflammatory and autoimmune diseases. Lastly, we anticipate a possible presentation from the ongoing Phase 1b efforts in psoriasis and atopic dermatitis with NKTR-358, with results from at least one of those studies slated for a medical meeting within the next 12 to 18 months. I'll now hand the call to Gil for a financial overview.
Gil Labrucherie
executiveBrian, thanks, and good afternoon to everyone. We put out our earnings press release earlier today, which included the complete 2020 financial results for the full year. In this call, I'll briefly recap the royalty monetization transaction that closed as 2020 came to an end, and then I'll take you through the annual financial guidance we're providing for 2021. We completed a $150 million royalty monetization with HealthCare Royalty Partners on December 30, 2020, which made our balance sheet even stronger. The royalty interest involved in that transaction originated from our license agreement with AstraZeneca for MOVANTIK, as well as the license agreements covering our PEGylated Factor VIII portfolio, which primarily consist of royalties from Takeda related to ADYNOVATE. A crucial feature of this arrangement is that after the agreed cash-on-cash return ceilings are reached, Nektar regains the rest of the royalties. With the $150 million generated by monetizing this royalty, plus the $250 million of senior notes we had already paid off earlier in the year, we ended 2020 financially solid — holding $1.2 billion in cash and investments while carrying no debt. Turning to what we project for 2021: we anticipate closing the year with approximately $750 million in cash and investments. If you factor in the $250 million of senior debt we paid down during 2020, the royalty monetization deal we closed that same year, and the $50 million in milestone payments from BMS in 2020 linked to kicking off the MIBC and adjuvant melanoma registrational trials, then our cash burn for 2021 looks pretty steady compared with the prior year. The main reason is that patient enrollment in the Phase 3 trials for bempeg has climbed a lot higher, and on top of that, clinical development activity for NKTR-255 has been scaling up. Prior to discussing our full-year financial outlook, I'd like to take a moment to walk through the anticipated accounting treatment for two sets of agreements. The first is the co-development and funding arrangement we announced last week with SFJ Pharmaceuticals, together with its financial sponsors Blackstone Life Sciences and Abingworth. The second is the clinical trial and supply collaboration with Merck. Thanks to these partnerships, a new Phase 2/3 registrational trial of bempeg combined with pembrolizumab in head and neck cancer patients will begin this year. As part of the arrangement, SFJ has pledged to operationalize and provide $150 million in funding for the registrational study, while Merck will supply pembrolizumab at no cost. Success payments for SFJ would only come due if the FDA approves bempeg in first-line metastatic melanoma, head and neck cancer, or a single additional bempeg indication. Since SFJ is bankrolling the head and neck cancer study, those sums will show up in our R&D expense and also within the derivative liability I'll walk through shortly — though because SFJ covers that share of our R&D expense, it will register as a non-cash expense. Our expectation is to treat these contingent success-based payments owed to SFJ as a derivative liability. Down the road, we will assess the odds that SFJ gets those success payments, and we will put that cost on our income statement, paired with an offsetting increase to a derivative liability, based on a probability weighted and adjusted discounted cash flow model that we review every quarter. With Merck's robust support, which substantially reduced the total expense of the head and neck trial, plus the risk-reward financing structure we have with SFJ, which allowed us to bring an additional, very sizable indication opportunity into the bempeg portfolio, we are feeling quite optimistic. Our R&D spending for 2021 will drive our deep pipeline and clinical development strategy considerably further forward. Right now, six registrational trials for bempeg are being funded by us and our partners, including the head and neck study that was announced not long ago. Together with Lilly, four studies for NKTR-358 are in progress, and we also have two broad Phase 1/2 trials of NKTR-255 that span hematologic and solid tumor settings. Beyond that, our early research efforts will continue so that new programs can enter the pipeline via planned IND filings in 2022. Finally, in parallel with these major R&D programs, commercial readiness activities appropriate to our stage will move forward, with focus on distribution capability, preparation for market access, and the other requirements that would support a bempeg launch as early as the end of 2022. Now let's move on to the GAAP annual financial guidance we're providing. When we look at the entire 2021 fiscal year, we're projecting GAAP revenue of approximately $100 million. Within that total, somewhere between $15 million and $20 million should come from product sales, while $80 million to $85 million is expected as non-cash royalty revenue generated by the royalty monetization transactions from 2012 and 2020. On the GAAP R&D expense side for 2021, we anticipate a figure in the $450 million to $500 million range. That range encompasses roughly $55 million in non-cash depreciation and stock compensation expense, plus about $30 million in non-cash development expenses associated with the bempeg head and neck study. For 2021, we anticipate G&A costs will fall somewhere in the range of $120 million to $125 million. Within that figure, approximately $45 million comes from non-cash items — specifically depreciation and stock compensation. As for non-cash interest expense, it should be somewhere between $50 million and $60 million, and it relates to monetizing our royalty streams. Additionally, we expect to record a non-cash charge each quarter, amounting to about $15 million across the full year, associated with the derivative liability from our funding agreement with SFJ for the bempeg head and neck studies. With that said, let's begin taking questions. Operator?
Peter Lawson
analystHello, and many thanks. Regarding the PROPEL study, it appears that it got pushed back. I'm curious whether you might walk us through the reasoning there — is this a case of favorable tidings arriving later, or simply an excess of prudence?
Jennifer Ruddock
executiveSure. Appreciate that, Peter. I'll hand this one over to JZ to respond to. JZ, would you bring us up to speed on what we shared back in January of this year? Thank you.
Jonathan Zalevsky
executiveAbsolutely, Peter — I appreciate the question. One positive development from that study was that as COVID began to subside across Europe, enrollment from European sites picked up remarkably quickly. The result was that during the final 2 months of 2020, patient accrual happened at a very rapid pace, and roughly 60 patients were enrolled into that trial. What that means is that the patient population is now in the study, but they came in only within the past couple of months. Our goal is to deliver the strongest, most comprehensive data set we possibly can. With the number of patients enrolled, it matters a great deal that each patient remains in the study long enough for follow-up duration and treatment duration to be extended. When we report data, our aim is to include a minimum of 2 scans for every patient enrolled in the study. That is why we set our target on the second half of the year — to give the most thorough, complete, and mature data set possible. As for the type of information we intend to share later this year, the study divides patients among the different PD-L1 expression subgroups: below 1%, 1% to 49%, and at or above 50%. We would plan to report response rates, plus the proportion of patients achieving a deep response, including CRs, the duration of response, any accumulated longer-term follow-up data that is available beyond just the ORR, along with the safety profile and additional translational biomarkers. We look forward to presenting all of that later this year.
Jay Olson
analystHello, and congratulations on the Merck partnership for the combo trial in head and neck squamous cell carcinoma. Could you share your thoughts on what part HPV plays in that condition, and do you anticipate that patients testing positive for HPV might respond differently than those who are negative when treated with bempeg? Also, perhaps you could explain how bempeg might stand apart from IL-15 in that context? Thanks.
Jennifer Ruddock
executiveJZ, would you handle that?
Jonathan Zalevsky
executiveAbsolutely. Yeah, I appreciate that question. It's a really thoughtful one. So, something quite interesting regarding this particular tumor type is that how the disease shows up has evolved over time, correct? At one point, most patients were smokers, and you'd observe this and connect it to lifestyle, yet over roughly the past 20 years, there's been a significantly larger rise in patients with HPV involvement, a lot of them younger and perhaps not necessarily smokers, but they still come in with the disease. So HPV status, correct, serves as a key driver, and it plays a major role in the patient population within the study; therefore, those individuals are certainly part of it. When it comes to how their disease presents, there are certain distinctions that are quite clever to pay attention to; so, we already know this tumor type is immune-sensitive, and we know these patients tend to have a fairly high mutational burden; so, what you see among HPV patients is that they carry extra viral antigens, correct. As a result, you could potentially get an even stronger T cell response among those whose tumors are HPV-positive. That was definitely part of our thinking around how bempeg works, given the T cell priming it triggers, since we recognized HPV-positive patients would carry additional tumor-associated antigens for priming T cells against, so that's absolutely something we think about a great deal; and then we're concentrating on bempeg for this tumor indication. It's given alongside a checkpoint inhibitor, correct, with PD-1 and pembro. We genuinely believe that's far more a bempeg-driven mechanism rather than, strictly speaking, for 255. But with 225, correct, we're looking at other indications even though head and neck is also being used in the study, where we combine it with cetuximab. In that case we're going after second line or beyond, and we're going after the refractory population. And how 255 works in that context is essentially to boost the ADCC component of tumor targeting tied to cetuximab. So they're essentially two distinct mechanisms meant to produce two distinct types of combination owing to the different combination partners. And then, naturally, the different line of therapy as well. Thanks for your question.
Jessica Fye
analystHello everyone. Good evening, and thanks for taking my questions. In connection with the discussions about the head and neck study, did Merck have visibility into any of the PROPEL lung data that you're producing with pembro? Also, could you remind us what the pembro monotherapy benchmarks are for each PD-L1 expression level in PROPEL?
Jennifer Ruddock
executiveHoward, please handle the first portion of that question. And JZ, would you take the second part.
Howard Robin
executiveAbsolutely, Jessica. So here's the thing — before Merck got into that big collaboration, they definitely invested a lot of effort into due diligence on bempeg. Keep in mind, they're supplying the drug for a trial involving 500 patients, and even though it's impossible to pin down how many vials or the precise figure, a rough estimate puts it at somewhere from $50 million to $70 million in drug product. So it's clear they did a thorough evaluation of bempeg, and my sense is they have strong conviction in the mechanism. Whether they've reviewed the lung data, I honestly can't say — that hasn't been made public at this point — so I think the only reasonable assumption is that they've examined whatever is available for them to examine.
Jennifer Ruddock
executiveJZ, you want to talk about the benchmarks for pembro for monotherapy?
Jonathan Zalevsky
executiveIndeed, Jess, those figures come out of a range of Keynote trials. In the earliest one, KEYNOTE-001, a modest amount of information existed regarding single-agent pembro among those whose PDL was under 1%. In that group, a response rate of roughly 7% to 8% was observed with single-agent pembro. Naturally, in that context pembro gets paired with chemo — that's the combination they examined — yet single-agent pembro yielded 7% to 8%. Regarding the 1% to 49% group, findings from KEYNOTE-42 indicated an ORR of approximately 17% on single-agent pembro. Then, within the greater than or equal to 50% subgroups, we have results from both KEYNOTE-24 and KEYNOTE-42, and those fall in the 40% to 45% range for ORR. Such bars, or metrics, or benchmarks are what we're drawing on to set the PROPEL data side by side with the single-agent pembro data across each of those distinct PD-L1 subgroups.
Paul Choi
analystWe appreciate you fielding our inquiries, and we celebrate everything that has been accomplished during 2020. Perhaps we could revisit your work with Merck involving head and neck cancer, and more specifically, how you go about identifying patients who are front-line. Based on what the market data indicates right now, PD-1 therapy already accounts for more than 50% within that front-line setting. So could you perhaps begin by sharing your thinking on the recruitment schedule for your Phase 2 and Phase 3? And then, relative to the monotherapy arm included in the study, what kind of margin would you be seeking when conducting your interim futility analysis? Many thanks.
Jennifer Ruddock
executiveThank you, Paul. JZ, I would like you to offer some thoughts regarding the enrollment plan. Appreciate it.
Jonathan Zalevsky
executiveOkay, yes, thanks, Paul. So about 80% to 85% of head and neck cancer patients truly are PD-L1 positive; they'll have a combined CPS score of at least one; therefore it's quite immune-sensitive. Plus, this tumor type already shows a fairly elevated baseline of positivity; and what we learned from an earlier Merck Keynote study is that the patient distribution — let's say the two groups Merck used, the 1 to 19 and the above 20 CPS split — was roughly 50 to 50 within that population; so that's a fairly large share, correct. Those who essentially meet the criteria, nearly all of them will have a CPS score allowing entry into the study. So we believe there's a genuinely strong chance to get this trial enrolled rather rapidly since, on top of that, each patient receives either the standard of care pembro or the experimental arm, which is pembro plus bempeg. Thus it's the standard of care along with a mechanism that might deliver synergy; so this is a very attractive possibility for patients; and it's a very attractive possibility for physicians, right, since the chance to place a patient on a trial where they'll receive standard of care or standard of care plus, I mean, that's simply a very favorable situation. So we anticipate this trial may enroll quite fast; and then, I apologize, I missed the second portion of your question. Would you mind repeating it, Paul?
Paul Choi
analystRegarding the interim or futility analysis, what margin would you be looking for? Thank you so much.
Jonathan Zalevsky
executiveYeah. All right. Thanks. My apologies — I didn't catch that. So, yes, a futility boundary is prespecified, and it occurs once 200 patients have been enrolled and followed for a brief period, with ORR used for assessment. We haven't provided any sort of guidance regarding what that futility margin actually is. But obviously, it forms a component of the study design. It's something that gets discussed with health authorities, and it's something we discuss with Merck too. And obviously, it's a component of the statistical analysis plan for the study. Thanks for the question.
Difei Yang
analystHello, and good afternoon. I appreciate you taking my question. What I'd like to ask about is really the CMC for 358. Would you anticipate that producing 358 will be just as difficult as bempeg was a couple of years ago? Thank you.
Jennifer Ruddock
executiveThank you, Difei. JZ, I'd like you to say a few words on this.
Jonathan Zalevsky
executiveSure thing, yes.
Jennifer Ruddock
executiveNo problem.
Jonathan Zalevsky
executiveHello Difei, and thanks for bringing that up. The 358 molecule differs substantially from bempeg. To begin with, both of them are interleukin-2, correct. So where fermentation is concerned, there's no distinction at all. The PEG, though, is an entirely different story. As an example, with bempeg you're aware that the PEG can be released, while with 358 the PEG is stable — the linkage there doesn't break. You're also aware that bempeg functions as a prodrug, and here too 358 is not the same. This one acts immediately once present; so it's a very different beast; and it falls under an entirely separate group of controls, covering in-process matters as well as a wholly distinct release specification set. One more thing I'd say matters here: under the structure of our arrangement with Eli Lilly, Phase 1 execution sat with Nektar, and manufacturing through the initial portion of Phase 2 was ours as well. Once that point passed, though, Lilly took over the whole program. As a result, Lilly today carries the responsibility for running not just the clinical study but the production of NKTR-358 too. Naturally, they're scaling it up and transitioning it into commercial manufacturing.
Howard Robin
executiveHoward here. Let me tack on one additional point regarding that. When you think about the bempeg production problem—which obviously is what you're referring to—I'd like to remind everyone that this involved a single faulty batch of intermediate material that sadly ended up being used in two clinical trial production lots. Those, however, were defective batches produced back in 2016. As a result, that matter has been fixed and is far in the past now. I recognize it surfaced in a horrible fashion. Yet the production difficulties stemmed from one poor intermediate batch. Nothing we manufacture at Nektar currently faces any production troubles or concerns. I simply wanted to state that plainly.
Andy Hsieh
analystThanks, that's helpful. I wanted to ask you, JZ — I believe you brought up the melanoma trial and went into some detail on the immune profile. For those 5 patients whose tumor size went down by 100% yet who didn't meet the criteria for CR, when it comes to durability and PFS, did their outcomes resemble a CR or more of a standard PR? I've also picked this up from other investigators — I'm curious whether fever might serve as an early stand-in signal of response, looking across all the bempeg studies you've reviewed.
Jonathan Zalevsky
executiveYes. Hello Andy, and thanks for those questions. I'll address them in 2 parts. First, what we observed in the melanoma data set, which we presented at SITC, was a notably prolonged PFS — 30.9 months. And if you examine part of that distribution, among patients with especially deep responses — whether that's 100% clearance of target lesions or the CRs — the pattern of separation matched what the FDA meta analysis showed. Durability was extremely high, and disease control lasted a very long time. In fact, among those patients with that degree of response depth, we have observed no relapse whatsoever; so yes, they behave very much like — again, in our data — a page taken from the meta analysis. Response depth has an exceedingly strong impact on both PFS and OS. And once you stratify those curves, that is precisely the picture that emerges. Turning to your second question, you've brought up a fascinating point. Going right back to the Steve Rosenberg studies using high dose IL-2 in 1980, there has been intense interest in finding correlates of immune activation — be they AEs, cell types, or something else — to determine whether such AEs or cytokine-related activity measurable alongside the clinical picture track with response. Convincing publications are honestly lacking, but researchers have examined things such as pruritus, the cytokine itch, and the cytokine skin reactions one can observe. Eosinophil counts have been studied too, since as we know the IL-2 pathway can induce them. I should say we lack a clear trend in our data sets that we could single out. Still, the empirical observations made in the clinic — like what the investigators you're talking with are reporting — are empirically in line with that idea. Those patients showing very pronounced cytokine-related AEs, which may appear as flu-like symptoms, may appear as fever, may appear as various kinds of rashes. There could be certain patterns connecting those sorts of external signs, yet nothing stands out when you run the statistics. They're the sorts of patterns that especially skilled doctors — the ones who truly care for their patients, nail the diagnosis, and handle bedside interactions exceptionally well — are able to notice, though making those sorts of inferences statistically is far more difficult. What truly excites us: as you'll recall from our SITC presentation, within our data set we identified 2 on-treatment early detection biomarkers that appear strongly linked to patients who ended up responding. Those were reported during Adi's presentation. So, as a reminder, Adi described eosinophilic increases observed in patients following bempeg very early, right within the first cycle, appearing weeks before the initial scan, suggesting they might serve as a potential predictive biomarker for patients who ultimately respond. The other biomarker, which strikes me as even more compelling, was the single cell cytokine data, revealing that within CD8 T cells, the polyfunctional strength index rose quite dramatically merely a week after the initial bempeg treatment among patients who eventually responded and even achieved a first scan showing positive tumor shrinkage. Thus, those were 2 further biomarkers we presented that proved genuinely interesting. And particularly with the single-cell cytokine, rather novel information that was highly prognostic in potentially forecasting early responses. Yes. Thank you, Andy.
Ben Burnett
analystH. Thanks a lot. A quick one about the 358 program. I suppose as you take it past lupus into those other disease settings, how are you thinking about a dosing schedule for 358? And does the Phase 1 tell us anything useful there?
Jennifer Ruddock
executiveYes. Thanks, Ben. Brian, I want you to handle that one, if you would.
Brian Kotzin
executiveAbsolutely, happy to address that. To start with, the Phase 1 trial certainly provided valuable data. Essentially, it delivered a great deal of insight into how dosage relates to the triggering of regulatory T cells and the extent of that triggering. We also learned how far the dose can be escalated while preserving exquisite selectivity, targeting only the stimulation of regulatory T cells. And as you're aware—or I hope you're aware—the tolerability was really quite good. That gave us confidence to carry every dose examined in the Phase 1 program forward into later-stage trials. So in those later-phase studies, essentially all of them were designed to determine—and we still don't know, for each of those diseases, which doses are most likely to produce the greatest clinical benefit. Is it the top dose that yields the largest number of Tregs? Is it a mid-range dose that produces merely elevated levels? Or is it a low dose that activates regulatory cells only modestly? And the exquisiteness, the selectivity, may also be somewhat reduced at the highest dose compared with the middle dose. So right now, that's precisely what we need to determine. And regarding your question, I'd add that we don't know whether various diseases might require different dose levels to maximize clinical response. I think that's what makes doing this broad scope and examining multiple Phase 2 studies across a range of different indications so exciting. Thank you.
Howard Robin
executiveOkay, thanks to all of you for being here with us today. I want to give a special thank-you to the people who work here for sticking with it and putting in steady effort through what has been a really difficult period. The way they keep pushing our clinical trials forward while also keeping the business running smoothly is genuinely remarkable, and every single one of them deserves my thanks. Like I mentioned before, we're in a solid spot, with a healthy balance sheet and a pipeline of immuno-oncology and immunology programs that keeps maturing. We're grateful to our shareholders for standing behind us, and we look forward to bringing you more news about how things are going. This should be a fantastic year. We hope you and your loved ones stay safe and well; and once more, thank you for being with us.
Operator
operatorThat wraps up the conference call for today, folks. We appreciate everyone taking part, and at this point you're free to hang up. Have a great day, all of you.
Read the full transcript via the API
You're viewing the first half of this call. Get the complete Nektar Therapeutics transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.
Get the API View API docs →This call discussed
For developers and AI pipelines
Programmatic access to Nektar Therapeutics earnings transcripts and 132,000+ others is available through the
EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments,
full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.
More tools for stock research
OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Nektar Therapeutics or any ticker on your watchlist.
StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.